The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B ...

As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...

The three-dose hepatitis B vaccine has a long track record of safety, but rolling back recommendations could leave kids ...

The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

A combination treatment involving tobevibart and elebsiran significantly improved disease activity in adults with chronic ...

HCV—can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens ...

Hepatitis B vaccines given at birth have essentially eliminated the disease in kids. A vote this week could upend that ...

Of the 723 people with Fibrosis-4 Index scores greater than 3.25, indicating advanced fibrosis, and 587 people with diagnosed ...

Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...

The CDC's Advisory Committee on Immunization Practices will discuss hepatitis b shots for newborns and updates to ...

In this video, Mark Sulkowski, MD, discusses the AASLD updated practice guidelines on the treatment of patients with chronic hepatitis B.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global ...